The mutual fund company snapped up 2.3 million shares between July and September and now controls 12.7 percent of the Danvers, Mass.-based cardiac assist device maker.
Portfolio managers with the Boston-based mutual-fund giant have been big buyers of Abiomed stock this year, purchasing over 2.35 million shares of the Danvers, Mass.-based device maker during the three months ended Sept. 30. That follows a 2.1-million-share buying spree during the prior quarter, boosting the funds' overall stake to 4.75 million shares, according to new stock ownership reports.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...